Glucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide and saxagliptin, are emerging antidiabetic drugs that show promise in improving IR in AP patients. The gene discussed is GLP1R; the disease is alkaline phosphatase measurement.